Related Experiment Video
Updated: Mar 3, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
Paulina Chinchilla-López1, Xingshun Qi2, Eric M Yoshida3
1Liver Research Unit. Medica Sur Clinic & Foundation, Mexico City, Mexico.
Abstract:
The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon-based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.
Related Concept Videos
Retrovirus Life Cycles
Mechanisms of Retrovirus-induced Cancers
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antihypertensive Drugs: Direct Renin Inhibitors
Hepatic Drug Excretion: Influencing Factors
Viruses with RNA Genomes

